CSRxP: SENATE JUDICIARY COMMITTEE MUST REJECT BIG PHARMA’S FALSE RHETORIC ON INNOVATION, HOLD BRAND NAME MANUFACTURERS ACCOUNTABLE FOR PATENT ABUSE
Big Pharma’s Anti-Competitive Tactics That Extend Monopolies Are… Read More

Big Pharma’s Anti-Competitive Tactics That Extend Monopolies Are… Read More
Committee Markup Advances Solutions to Crack Down on Big Pharma’s Patent… Read More
Lawmakers Should Advance Biosimilar Red Tape Elimination Act, Medication… Read More
Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. Ruling Will Help Protect… Read More
Lawmakers Should Advance the ETHIC Act and Skinny Labels, Big Savings Act to… Read More
Lawmakers Should Reject Big Pharma’s Debunked Rhetoric on Innovation… Read More
Administration and Congress Must Enact Market-Based Solutions to Hold Big… Read More
Campaign Encourages E&C Lawmakers to Focus on Big Pharma’s… Read More
Campaign Appreciates Administration’s Commitment to Lowering Drug Prices,… Read More
Congress Passes Reforms to Increase Transparency, Prevent Big Pharma from… Read More
Bipartisan, Market-Based Solution Would Increase Transparency… Read More
Campaign Introduces “Phil the Pill” as New Character Personifying How Big… Read More